11:50 AM EDT, 10/28/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

After reviewing Q3 results and this morning's analyst call, we raise our target price to $254 from $216, 19.7x our 2026 EPS, a discount to IQV's five-year historical forward P/E average of 20.6x. We maintain our 2025 EPS at $11.96 and 2026 EPS at $12.88. IQVIA ( IQV ) delivered solid Q3 2025 results with stronger R&D Solutions net bookings of $2.6 billion (up 13% year-over-year), and a solid backlog of $32.4 billion, up 4.1% Y/Y, providing healthy future revenue visibility, in our opinion. We think that the company will continue to benefit in the next quarters from improving market dynamics, normalizing market conditions, and reduced client uncertainty as large pharmaceutical customers are completing their pipeline reprioritizations. We continue to be bullish on IQV shares after reviewing Q3 results, as we see IQVIA ( IQV ) as well positioned for sustainable growth with a strong track record of execution and innovation.